VEL015: a novel inhibitor of PI3k/Akt signalling inhibits the progression of prostate cancer and sensitises to existing therapies

Abstract

Introduction:  Overactivity of PI3K/Akt signalling is firmly implicated in the progression of lethal prostate cancer. We report on VEL015, a water soluble, orally active agent that blocks PI3K/Akt signalling at the level of Akt and its effects on the progression of experimental prostate cancer. Methods:  The effects of VEL015 on key components of PI3K/Akt signalling were determined by western blotting with activation state‐specific antibodies and direct in vitro enzymatic assays. Resultant biological effects were determined by proliferation and apoptosis a..